OncoMatch/Clinical Trials/NCT06721286

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

Is NCT06721286 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Teripalimab and Gemcitabine + Cisplatin for intrahepatic cholangiocarcinoma (icc).

Phase 2RecruitingTianjin Medical University Cancer Institute and HospitalNCT06721286Data as of May 2026

Treatment: Teripalimab · Gemcitabine + Cisplatin — This study was a randomized controlled trial to evaluate the efficacy and safety of toripalimab combined with GemCis (gemcitabine and cisplatin) as preoperative neoadjuvant therapy for resectable ICC at high risk of recurrence.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cholangiocarcinoma

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: PD-1/PD-L1/PD-L2/CTLA-4 or other stimulatory or co-inhibitory T cell receptor therapy

Patients who received PD-1, PD-L1, PD-L2, CTLA-4 before enrollment, or directly received another stimulatory or co inhibitory T cell receptor (such as CTLA-4, 0X40, CD137)

Cannot have received: investigational agent

Any other research drugs within 4 weeks before enrollment

Lab requirements

Blood counts

The main organs function normally, and there is no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities

Kidney function

The main organs function normally, and there is no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities

Liver function

The main organs function normally, and there is no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities

Cardiac function

The main organs function normally, and there is no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities

The main organs function normally, and there is no serious blood, heart, lung, liver, kidney, bone marrow and other functional abnormalities and immune deficiency diseases.

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify